Table 1.
Patient baseline characteristics
| Factors | Received curative conversion and achieved clinical CR (n = 38) | Did not receive curative conversion or did not achieve clinical CR (n = 72) | p value |
|---|---|---|---|
| Age | |||
| Years old, median (IQR) | 77.0 (71.8, 81.0) | 75.6 (69.3, 81.0) | 0.379 |
| Sex | |||
| Male/female | 32/6 | 50/22 | 0.125 |
| ECOG PS | |||
| 0/1 | 27/11 | 60/12 | 0.105 |
| BMI | |||
| kg/m2, median (IQR) | 25.2 (22.5, 27.8) | 23.7 (22.3, 26.5) | 0.160 |
| Etiology | |||
| HBV/HCV/AL/NAFL/other | 3/15/9/9/2 | 13/26/13/16/4 | 0.172 |
| BCLC stage | |||
| A/B up-to-7 IN/B OUT | 4/9/25 | 2/18/52 | 0.230 |
| Tumor size | |||
| cm, median (IQR) | 4.0 (2.6, 5.1) | 3.8 (2.4, 6.0) | 0.841 |
| Tumor number | |||
| 1/2-3/4-6/7- | 8/16/10/4* | 8/19/18/27* | 0.018 |
| ALBI score | |||
| Median (IQR) | −2.76 (−2.93, −2.38) | −2.65 (−2.87, −2.23) | 0.206 |
| NLR | |||
| Median (IQR) | 2.15 (1.36, 3.25) | 2.74 (1.81, 3.73) | 0.145 |
| PLT | |||
| Median (IQR) | 14.1 (12.8, 18.3) | 14.5 (10.9, 18.0) | 0.624 |
| PT-INR | |||
| Median (IQR) | 1.07 (1.00, 1.15) | 1.1 (0.99, 1.13) | 0.624 |
| ALB | |||
| g/dL, median (IQR) | 4.1 (3.7, 4.3) | 4.0 (3.6, 4.2) | 0.377 |
| T-bil | |||
| mg/dL, median (IQR) | 0.7 (0.5, 0.9) | 0.8 (0.6, 1.1) | 0.354 |
| CRP | |||
| mg/dL, median (IQR) | 0.19 (0.11, 0.42) | 0.19 (0.09, 0.39) | 0.941 |
| ALT | |||
| U/L, median (IQR) | 31.5 (18.8, 49.3) | 32.5 (25, 42.5) | 0.624 |
| AFP | |||
| ng/mL, median (IQR) | 11.0 (3.5, 209) | 75 (7.3, 764) | 0.057 |
| DCP | |||
| mAU/mL, median (IQR) | 382 (40.5, 2026) | 319 (74.9, 2197) | 0.901 |
ALBI; albumin‐bilirubin, NLR; neutrophil to lymphocyte ratio, ALT; alanine aminotransferase, AFP; alpha-fetoprotein, DCP; des-gamma‐carboxy prothrombin.